Clinical Trial Update: A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration [Phase 4]

View source ↗

Summary

A 52-week open-label Phase 4 trial evaluated memantine for frontotemporal dementia and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Frontotemporal Dementia

Drugs mentioned

• Memantine (memantine)

Snippet

Sponsor: University of California, San Francisco | Conditions: Frontotemporal Lobar Degeneration | Phase 4 | Status: COMPLETED